That emerging and small biopharma companies, or rather, their individual products, will be the future pipelines of big Pharma, appears inevitable. The nimble and efficient smaller companies can create new pharmaceutical”
“Products more cheaply and quicker than their giant forerunners. The pattern may be emerging that the Skunk Work companies create, while the Big Guys market. This would be a happy outcome for everyone.
http://lnkd.in/NytvX5
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022